Literature DB >> 15380580

Intervention after PSA failure: examination of intervention time and subsequent outcomes from a prospective patient database.

Charmaine Kim-Sing1, Tom Pickles.   

Abstract

PURPOSE: To investigate timing of intervention for solitary biochemical relapse following external beam radiation therapy (EBRT) for localized prostate cancer, and to assess the impact on survival. METHODS AND MATERIALS: Of 1499 men treated with EBRT from 1994 to 2000, 544 men had prostate-specific antigen (PSA) relapse by the Vancouver Criteria. Patients with near-simultaneous clinical relapse (n = 79) were excluded, leaving 465 for analysis. Pretreatment prognostic factors, the time that biochemical relapse was realized (trigger PSA time), and postrelapse doubling time (PSAdt) were examined for effect on the timing of intervention and cause-specific survival (CSS).
RESULTS: Median actuarial time from trigger-PSA time to intervention was 30 months. The only factor associated with early intervention on multivariate analysis (MVA) was faster PSAdt (p < 0.0001). Not significant were initial PSA, Gleason score, T stage, or adjuvant androgen ablation use or duration. Seventy-five percent of interventions occurred with PSAdt faster than 12 months. The 5-year CSS was 89%. Faster PSAdt (p = 0.0007), higher Gleason score (p = 0.018), and earlier intervention (p = 0.0006) were significantly associated with increased prostate cancer death on MVA. The 5-year CSS is 19% where the PSAdt was <3 months, 84% where 3-6 months, 93% where 6-12 months, and 98% where >12 months (p < 0.0001).
CONCLUSIONS: Men with a biochemical relapse post-EBRT with PSAdt >1 year had excellent 5-year CSS (98%). Rapid PSAdt is associated with increased mortality on MVA. The association of earlier intervention with increased mortality may be due to the selection of those with occult metastasis for early intervention.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15380580     DOI: 10.1016/j.ijrobp.2004.03.004

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  12 in total

Review 1.  [Local recurrence of prostate cancer: hormone therapy].

Authors:  J E Altwein; T Ebert
Journal:  Urologe A       Date:  2006-10       Impact factor: 0.639

2.  Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database.

Authors:  Emmanuel S Antonarakis; Yongmei Chen; Sally I Elsamanoudi; Stephen A Brassell; Mario V Da Rocha; Mario A Eisenberger; David G McLeod
Journal:  BJU Int       Date:  2010-11-23       Impact factor: 5.588

3.  Hormone use after radiotherapy failure: a survey of Canadian uro-oncology specialists.

Authors:  D Andrew Loblaw; Tom Pickles; Patrick C Cheung; Himu Lukka; Sergio Faria; Laurence Klotz
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

4.  PSA Doubling Time Predicts for the Development of Distant Metastases for Patients Who Fail 3DCRT Or IMRT Using the Phoenix Definition.

Authors:  Tracy L Klayton; Karen Ruth; Mark K Buyyounouski; Robert G Uzzo; Yu-Ning Wong; David Y T Chen; Mark Sobczak; Ruth Peter; Eric M Horwitz
Journal:  Pract Radiat Oncol       Date:  2011

5.  The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up.

Authors:  Emmanuel S Antonarakis; Zhaoyong Feng; Bruce J Trock; Elizabeth B Humphreys; Michael A Carducci; Alan W Partin; Patrick C Walsh; Mario A Eisenberger
Journal:  BJU Int       Date:  2011-07-20       Impact factor: 5.588

Review 6.  Management Options for Biochemically Recurrent Prostate Cancer.

Authors:  Farhad Fakhrejahani; Ravi A Madan; William L Dahut
Journal:  Curr Treat Options Oncol       Date:  2017-05

7.  Predicting biochemical failure and overall survival through intratherapy PSA changes during definitive external beam radiotherapy.

Authors:  Daniel E Soto; Rebecca R Andridge; Jeremy M G Taylor; Patrick W McLaughlin; Howard M Sandler; Charlie C Pan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-05-19       Impact factor: 7.038

8.  Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy.

Authors:  M T Schweizer; X C Zhou; H Wang; T Yang; F Shaukat; A W Partin; M A Eisenberger; E S Antonarakis
Journal:  Ann Oncol       Date:  2013-08-14       Impact factor: 32.976

9.  Prognostic Factors for Prostate Cancer Endpoints Following Biochemical Failure: A Review of the Literature.

Authors:  Tim Nguyen; R Gabriel Boldt; George Rodrigues
Journal:  Cureus       Date:  2015-01-05

10.  Natural history of untreated prostate specific antigen radiorecurrent prostate cancer in men with favorable prognostic indicators.

Authors:  Neil E Martin; Ming-Hui Chen; Clair J Beard; Paul L Nguyen; Marian J Loffredo; Andrew A Renshaw; Philip W Kantoff; Anthony V D'Amico
Journal:  Prostate Cancer       Date:  2014-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.